Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease
Open Access
- 29 July 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (8) , ofab393
Abstract
We report a patient with connective tissue disease who developed modest severe acute respiratory syndrome coronavirus 2 receptor binding domain–specific antibody levels and a lack of neutralization capacity, despite having received 3 mRNA coronavirus disease 2019 vaccines and holding anti-B-cell therapy for >7 months before vaccination. The patient developed virus-specific T-cell responses.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01AI141003-03S1)
- Merck & Co
This publication has 13 references indexed in Scilit:
- Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory diseaseAnnals of the Rheumatic Diseases, 2021
- SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseasesAnnals of the Rheumatic Diseases, 2021
- A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 PatientsJournal of Clinical Microbiology, 2021
- Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipientsAmerican Journal of Transplantation, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant RecipientsJAMA, 2021
- T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responsesNature Communications, 2021
- Adaptive immunity to SARS-CoV-2 and COVID-19Cell, 2021
- Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing TitersJournal of Clinical Microbiology, 2021